Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Ibrutinib (IMBRUVICA®) Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease Data presented today at the American Society of Clinical Oncology Annual Meeting - This...
Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA®) Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small...
Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for Patients with Two Relapsed/Refractory Blood Cancers PR Newswire SUNNYVALE, Calif., May 28, 2015...
European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) to Treat Waldenstrom's Macroglobulinemia Would Become First EMA-approved Therapy for Patients...
New ibrutinib (IMBRUVICA®) Data to be Showcased at American Society of Clinical Oncology (ASCO) Annual Meeting IMBRUVICA Combination Data in Chronic Lymphocytic Leukemia to be Featured in...
Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates PR Newswire SUNNYVALE, Calif., May 1, 2015 SUNNYVALE, Calif., May 1, 2015 /PRNewswire/ -- Pharmacyclics...
Ibrutinib (IMBRUVICA®) Improves Outcomes for Pancreatic Ductal Adenocarcinoma in Mouse Models - Note: This press release corresponds to abstract 396 PR Newswire PHILADELPHIA, April 20, 2015...
IMBRUVICA® (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, in Patients with Chronic Lymphocytic Leukemia (CLL) Oral Presentation at the...
New Longer-Term IMBRUVICA® (ibrutinib) Data Show High Response Rates in Patients with Waldenstrom's Macroglobulinemia Data Published in The New England Journal of Medicine Show 91% Overall...
Solid Tumor Study Investigating Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Commences in Patients with Relapsed/Refractory Non-Small Cell Lung, Breast and Pancreatic...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
